SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress…

Posted: August 22, 2022 at 2:55 am

Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an Oral Presentation on Saturday, September 10 (16:55 CEST; 10:55 a.m. ET) Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an Oral Presentation on Saturday, September 10 (16:55 CEST; 10:55 a.m. ET)

Continued here:
SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress...

Related Posts